BPC-157 in the US, 2026: Regulatory Status and What the Preclinical Literature Supports

• ·BPC-157 is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) derived from a protein fragment originally described in human gastric juice.
• ·In 2026 the FDA removed it from Category 2 (April), and its Pharmacy Compounding Advisory Committee (PCAC) voted 8 in favor, 6 against, with 1 abstention, to recommend it for the 503A bulks list (July). Neither step made it an approved drug.[1][2]
• ·The research base is predominantly preclinical and mostly in rodents, and much of it comes from a single research group; only a handful of groups have studied the peptide in depth.[3]
• ·Reviews consistently call for controlled human studies and independent replication before conclusions can be drawn.[3][4]

Early studies noted BPC-157's apparent stability in human gastric juice, which is part of why researchers have examined it by several routes in animal models. Its identity data:

• ·Name. BPC-157 (Body Protection Compound 157; also designated PL 14736).
• ·Sequence. Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
• ·Length. 15 residues.
• ·Molecular weight. 1419.5 g/mol for the free peptide, C₆₂H₉₈N₁₆O₂₂.
• ·Form supplied. Lyophilized powder, typically the acetate salt.

Research Material

Amino Acid Sequence

Chemical Structure

The FDA side of the story comes down to four dates. For detail on each step, see our posts on the April 2026 Category 2 removals and the July 2026 PCAC vote.

• ·2023. Placed in Category 2 of the FDA's interim 503A bulks list, the category for substances that raise significant safety concerns. In practice this barred compounding pharmacies from using it.[1]
• ·15 April 2026. The FDA announced its removal from Category 2, after the original nomination was withdrawn. Removal does not make it eligible for compounding.[1]
• ·23 July 2026. The PCAC voted 8 in favor, 6 against, with 1 abstention, to recommend inclusion on the 503A bulks list. The vote is advisory only.[2]
• ·Pending. FDA notice-and-comment rulemaking, which is required before any change in compounding status.[2]

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157 for inclusion on the Section 503A Bulk Drug Substances List, alongside BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. FDA staff had recommended against inclusion for every substance under review, citing insufficient characterization, little or no human effectiveness evidence, and inadequate human safety data. The committee voted in favor anyway. The vote was 8 in favor, 6 against, 1 abstention.

Separately from FDA status, BPC-157 appears on the World Anti-Doping Agency Prohibited List, in class S0 (non-approved substances), which is relevant to any research involving athletes.[5]

The FDA's own meeting materials and the current text of the 503A list make the limits of the vote plain:[6][7][8]

• ·It is non-binding. The committee advises, it does not decide. No final FDA determination has been issued and none of the six peptides appears in 21 CFR 216.23.
• ·It requires a further step. Addition to the 503A Bulks List requires formal action by the Secretary of Health and Human Services, which had not occurred as of publication.
• ·It does not make the compound an FDA-approved drug, and it establishes nothing about efficacy.
• ·It does not legitimize research-chemical retail. A compounding-list decision concerns licensed pharmacists preparing patient-specific prescriptions under Section 503A, which is a different channel entirely from research material sold in vials.

Gwyer, Wragg and Wilson's 2019 review in Cell and Tissue Research summarized BPC-157 studies in musculoskeletal soft tissue, focusing on tendon, ligament and skeletal muscle injury models, mostly in small rodents.[3] A 2025 narrative review in Current Reviews in Musculoskeletal Medicine revisited the field with a focus on translation and risk.[4] The primary studies themselves are summarized in our BPC-157 research literature overview.

The main research themes are:

• ·Tendon and ligament models. Transection and detachment models in rats, with outcomes in histology, biomechanics and functional measures.
• ·Muscle injury models. Crush and transection injuries.
• ·Gastrointestinal models. Ulcer, fistula and anastomosis models, reflecting the compound's gastric origin.
• ·Proposed mechanisms. Interactions with the nitric oxide system, angiogenesis-related signaling (including VEGF pathways), and growth hormone receptor expression in tendon fibroblasts have all been proposed.[3][4]

FDA staff recommended against inclusion, and the committee vote that overrode them was narrow. The concerns raised at the meeting, about human safety data and characterization of the substance, are gaps the literature itself acknowledges.[2] The same reviews are explicit about what is missing:[3][4]

• ·Human data are very limited. The 2025 review counted three small human pilot studies and no large, controlled clinical trials.[4]
• ·Concentration of authorship. Much of the literature comes from one group, and only a handful of groups have studied the peptide in depth, which makes independent replication a priority.[3]
• ·Heterogeneous methods. Routes, models and outcome measures vary, which limits pooling.
• ·Mechanism is unsettled. Several pathways are proposed; none is established as primary.

• ·Characterize your lot. Record HPLC purity, mass-spec identity and measured content from the certificate. Purity and measured content answer different questions; see HPLC purity vs net peptide content.
• ·Control for endotoxin. Tissue repair and inflammation readouts are sensitive to LPS. Endotoxin screens are run on some lots rather than every lot, so check whether yours carries one before relying on it. See our endotoxin testing guide.
• ·Blind outcome assessment, and pre-register endpoints where possible.
• ·Report the salt form and how concentration was calculated. The Peptide Calculator covers stock concentration and mg to mM conversion.

Every BPC-157 lot is tested by Janoshik Analytical before sale, and the certificate is published as the laboratory reported it, verifiable on Janoshik's own site. The current certificate is below, with batch, HPLC purity and measured content read live from the batch record. Every lot is listed on the certificates of analysis page.

Published Certificate

Select strength

10mg12mg20mg

Batch

BPC-CA-25L-01

Purity (HPLC)

99.765%

Measured content

10.98 mglabeled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Available at Eppix Labs

BPC-157

10mg · 12mg · 20mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $49.99 USDIn stock